Longtime oncology commercial leader Chip Romp is making a creative leap and joining the board of directors at design-focused healthcare agency minds + assembly.
Pfizer`s blood cancer therapy Adcetris succeeds in late-stage trial
ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and dacarbazine (AVD; A+AVD) in adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma.1
The BrECADD combination comprised of brentuximab vedotin (Adcetris), etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone had noninferior efficacy and superior tolerability compared with escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial (NCT02661503) presented at the 17th International Conference on Malignant Lymphoma.1
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates during an Investor Day today focused primarily on the MM-120 (lysergide D-tartrate) program in generalized anxiety disorder (GAD).
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates during an Investor Day today focused primarily on the MM-120 (lysergide D-tartrate) program in generalized anxiety disorder (GAD).